Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of ...

The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) for BRCA-mutated early breast cancer and hormone-relapsed metastatic prostate cancer ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

A phase 3 trial evaluating olaparib (Lynparza) against standard of care chemotherapy in women with HER2-negative metastatic breast cancer has seen significant improvement in progression-free survival ...

"Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer." ScienceDaily. www.sciencedaily.com / releases / 2024 / 08 / ...

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer. At a median follow-up of 37.0 months, the median PFS was 11 ...

Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine ...

Please provide your email address to receive an email when new articles are posted on . The NOW trial demonstrated the feasibility of neoadjuvant therapy with olaparib for certain women with ovarian ...

Two interesting trials in ovarian cancer were presented yesterday with impressive results and a surprising prediction about their futures.Avastin (bevacizumab) and olaparib, a PARP inhibitor, were ...

The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, ...

Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum ...

Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to ...